2nd European Conference: Perspectives in Gynecologic Oncology

14. 1. 2005 - 15. 1. 2005, Palais de la Méditerranée, Nice, France

Informace k registraci

Registrace na místě bude možná následovně:
Pátek 14.1. 2005 12:00 – 18:00
Sobota 15.1. 2005 8:00 – 16:00
Odborný program na stránkách Imedex k vytištění

Friday, 14 January 2005


14:00
Welcome and introduction
Peter G. Harper, MD

Session I: Human Papillomavirus-associated Cancers

14:10
Debate: Patients with locally-advanced cervical cancer should undergo pre-treatment surgical staging
Pro: Dirk G. Kieback, MD, PhD
on: Fernando Mota, MD

14:50
Chemoradiation in cervical cancer
Christine Haie-Meder, MD

15:10
Systemic chemotherapy treatments in the prevention and treatment of cervical cancer
Jan B. Vermorken, MD

15:30
Surgery and radiotherapy in vulvar cancer
Ate G. van der Zee, MD

15:50
Break

Session II: Endometrial Cancer


16:10
Debate: Adjuvant radiotherapy should be standard treatment for high and low-risk patients
Yes: Peter Blake, MD, BSc, FRCR
No: Jean-Claude Horiot, MD, PhD

16:50
The current role of chemotherapy in endometrial cancer
Gunnar Kristensen, MD, PhD

17:10
The management of mesenchymal uterine tumors
Nick S. Reed, MD

17:30
Adjourn

17:35
Satellite Symposium

Saturday, 15 January 2005


Session III: Ovarian Cancer I


8:30
3rd International Ovarian Cancer Consensus Conference 2004: The Statements
Andreas du Bois, MD. PhD

9:00
Debate: Do patients who are adequately staged need chemotherapy?
Yes: Nicoletta Colombo, MD
No: Speaker invited

9:40
Molecular predictors of response
Silvana Canevari, MD

10:00
Break

10:20
Primary debulking versus interval debulking following neoadjuvant therapy
Primary: Damienne Castaigne, MD
Interval: Sergio Pecorelli, MD

11:00
Debate: Pros and cons of maintenance therapy
Pro: Jean Paul Guastalla, MD
Con: Martin Gore, MD

11:40
Lunch Symposium

Session IV: Ovarian Cancer II


13:30
Debate: Prolonging a platinum-free interval in recurrent ovarian cancer
Pro: Robert T. Morris, MD
Con: Eric Pujade-Lauraine, MD, PhD

14:10
Debate: Combination versus single agent therapy for recurrent ovarian cancer
Combo: Jacobus Pfisterer, MD
Single agent: Peter G. Harper, MD

14:50
New agents and new approaches to ovarian cancer
Stanley B. Kaye, MD

15:20
Concluding remarks
Stanley B. Kaye, MD

15:30
Adjourn

Web: http://imedex.com/...nts/egynonc05.html

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live